Transcutaneous carbon dioxide (PtCO 2 ) monitoring offers a potential non-invasive and continuous means to determine arterial carbon dioxide tension (PaCO 2 ). It was first developed in the 1970s in the neonatal intensive care setting to reduce arterial sampling. 1 The PtCO 2 monitor uses a thermostatically controlled heater unit that works on the principle that a heating element in the electrode elevates the temperature of the underlying skin. Under stable hemodynamic conditions, this increases the capillary blood flow and makes the skin permeable to CO 2 diffusion. This enables it to measure the CO 2 tension of the underlying skin tissue.
2 Figure 1 is a picture of the TOSCA TM 500 model of PtCO 2 monitor.
A number of studies have since reported good agreement between PtCO 2 and PaCO 2 values using Bland Altman analysis [3] [4] in various adult patient populations in the general ward, sleep study unit, respiratory care unit with non-invasive ventilation, critical care unit and operating theatre. [5] [6] [7] [8] [9] [10] [11] Studies investigating the use of PtCO 2 13 studied an ED population and reported a mean difference between the two measurements of 0.15 mmHg and 95% limits of agreement of ±6.84 mmHg. There were, however, some important limitations of their study. The sample size was relatively small (n=49) and not representative of the broad ED patient population. Patients were included only if they could give informed consent which might have excluded patients with higher degrees of hypercarbia. Also, a five minute lapse time from application of the monitor to arterial blood sampling was used in the study. Although this lapse time was more reflective of practical ED need for rapid information, it could affect the equilibration of the PtCO 2 monitor which usually takes 10-20 minutes. 2 In addition to the lack of ED studies on PtCO 2 monitoring, we have identified other considerations that would need to be addressed before it can be adopted for widespread ED use. Studies to date, both 3 ) which can detect a mixed acid-base disorder in patients with suspected hypercarbia.
It is also important to know the potential technical limitations of the specific PtCO 2 monitor. In addition to the need for an equilibration time of 10-20 minutes 2 upon initial application of the electrode on the patient, there are other technical drawbacks. These include the need for frequent (varying from once in 4 to 12 hours) re-calibration and changing of sites of placement to prevent burns or blistering of the skin, technical inaccuracies arising from trapped air bubbles, damaged electrode membranes and improper calibration or placement techniques 14 and the 'drift' phenomenon. The 'drift' phenomenon refers to the variation of PtCO 2 values with time. Although the newer PtCO 2 monitors with optical sensors are less affected by the drift phenomenon, 15 it differs among the electrochemical models and can be up to 5% over four hours. 16 Drift can affect the agreement between PtCO 2 and PaCO 2 values. Storre et al 6 reported a drift of 1.3 mmHg/hr over four hours that changed the limits of agreement from -1.7 to 7.5 mmHg to -3.9 to 13.2 mmHg between drift corrected and drift uncorrected values respectively. This may affect the usefulness of PtCO 2 monitoring in the ED over prolonged periods of time. In addition, further limitations arise because the PtCO 2 monitor does not contact expired air. It measures carbon dioxide tension in tissues overlying a capillary bed. Hence, unlike end tidal CO 2 , it cannot be used to confirm the intra-tracheal placement of the endotracheal tube or to detect ventilator disconnection. Also, its use in haemodynamically compromised patients with poor capillary refill appears to be unreliable. 12, 16 3 values in pVBG analyses in these patients can give insight to a concomitant metabolic acidosis. This, however, will require validation studies.
To date, the lack of ED studies, especially those looking at clinical outcome and treatment alteration, some technical and cost limitations make it difficult to recommend widespread use of PtCO 2 monitoring in the ED. Its future use in combination with pVBG remains to be validated.
